MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-05-2024
Nektar Therapeutics ROA Ratio 2011-2025 | NKTR
Annual ROA Ratio Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -69.36 | -51.82 | -46.89 | -28.88 | -22.29 | 31.69 | -19.0 | -26.99 | -16.17 | -12.21 | -37.28 | -34.52 | -22.09 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.69 | -69.36 | -27.37 |
Quarterly ROA Ratio Nektar Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.21 | -38.25 | -32.02 | -41.17 | -40.79 | -35.37 | -32.27 | -28.31 | -28.88 | -26.94 | -24.87 | -25.25 | -22.29 | -21.18 | -20.67 | 30.09 | 31.69 | 29.61 | 46.04 | -10.91 | -19.0 | -19.77 | -39.33 | -36.11 | -26.99 | -30.43 | -24.47 | -26.49 | -16.28 | -15.77 | 1.87 | 5.04 | -12.21 | -12.83 | -32.63 | -35.07 | -37.28 | -36.95 | -41.89 | -38.94 | -34.52 | -30.07 | -25.29 | -24.4 | -22.09 | -3.97 | -6.0 | -5.94 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 46.04 | -41.89 | -20.1 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
-11.97 | $ 3.56 | -2.51 % | $ 1.05 B |  Canada |
 |
AC Immune SA
ACIU
|
-27.92 | $ 2.82 | -2.07 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
-125.54 | $ 3.05 | 4.81 % | $ 40.2 K |  USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
Abeona Therapeutics
ABEO
|
-84.67 | $ 4.81 | -1.23 % | $ 103 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-2.11 | $ 11.96 | 0.13 % | $ 3.7 B | USA |
 |
Axcella Health
AXLA
|
-428.94 | - | -16.42 % | $ 249 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-634.44 | - | -2.5 % | $ 5.88 M | USA |
 |
argenx SE
ARGX
|
-14.32 | $ 901.39 | -1.59 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
-70.19 | $ 5.88 | 1.03 % | $ 212 M | USA |
 |
Achieve Life Sciences
ACHV
|
-153.92 | $ 4.69 | -1.88 % | $ 93 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-10.89 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 206.12 | -1.18 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.36 | -1.95 % | $ 8.08 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.54 | -1.92 % | $ 393 M |  Britain |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
-586.07 | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
-0.02 | $ 226.39 | -1.0 % | $ 400 B | USA |
 |
Cara Therapeutics
CARA
|
-94.17 | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-30.95 | - | - | $ 3.74 B | USA |
 |
Codiak BioSciences
CDAK
|
-21.64 | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-29.57 | $ 15.13 | -13.34 % | $ 2.23 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 3.37 | 3.47 % | $ 908 M |  Israel |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Biogen
BIIB
|
5.82 | $ 182.61 | 0.35 % | $ 26.6 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-34.81 | - | - | $ 7.29 B | USA |
 |
ContraFect Corporation
CFRX
|
-315.07 | - | -5.16 % | $ 5.39 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Beam Therapeutics
BEAM
|
-34.13 | $ 27.45 | -5.05 % | $ 2.26 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
6.11 | $ 53.01 | -1.51 % | $ 10.1 B | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 96.12 | 0.13 % | $ 27.2 B |  Germany |
 |
Clearside Biomedical
CLSD
|
-95.49 | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
-191.62 | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
-55.94 | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Chimerix
CMRX
|
-38.58 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-48.42 | - | - | $ 401 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-78.59 | $ 9.44 | -1.82 % | $ 611 M | USA |